Safety Monitoring Committee Recommends That Emergent BioSolutions Continue Its Hepatitis B Immunotherapy Phase II Trial
Emergent BioSolutions Inc. (NYSE: EBS) announced today that based upon recommendations from an independent Safety Monitoring Committee (SMC) the company is progressing into the next stage of the...
Emergent BioSolutions Announces That the Final Phase II Clinical Study Results for Typhoid Vaccine Reaffirms Clinical Endpoints Met; Immune Response Seen in 97% of Treated Subjects
Emergent BioSolutions Inc. (NYSE: EBS - News) announced today that the final analysis from a recently completed, randomized, placebo-controlled, blinded Phase II clinical study reaffirmed that its...
Emergent BioSolutions Announces Better-Than-Expected Preliminary 2007 Financial Results and Provides 2008 Guidance
Anticipates 2007 revenues of $183 million, net income of $21 to $24 million, year-end cash balance of approximately $106 million and stockholders' equity of approximately $169 to $172 million. 2008...
Emergent BioSolutions to Present at JPMorgan Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it will present at the 25th Annual JPMorgan Healthcare Conference in San Francisco. Fuad El-Hibri, president, chief executive officer and...
Emergent BioSolutions to Present at Upcoming Investor Conferences
Emergent BioSolutions Inc. (NYSE:EBS), announced today that company management will be presenting at the following two investor conferences over the next thirty day...
U.S. Department of Health and Human Services Remains Committed to Procurement of BioThrax(R) Under Current Contract
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Department of Health and Human Services (HHS) has reaffirmed its commitment to continue to purchase BioThrax(R) (Anthrax Vaccine...
Emergent BioSolutions to Lead a United States Delegation to the United States – India Business Council (a Subsidiary of the US Chamber of Commerce) Health Summit in India
Emergent BioSolutions, Inc. (NYSE:EBS) announced today that the company is leading a delegation to the United States - India Business Council's (USIBC) Healthy India Summit. Dr. Thomas Zink, the...
Emergent BioSolutions Announces Update on Department of Defense Procurement Strategy For BioThrax(R) (Anthrax Vaccine Adsorbed)
Emergent BioSolutions Inc. (NYSE:EBS) announced that it has been advised that the U.S. Department of Defense (DoD) intends to pursue a collaborative arrangement with the U.S. Department of Health and...
Emergent BioSolutions Completes Clinical Study in Support of a Post-Exposure Prophylaxis Indication for BioThrax(R) (Anthrax Vaccine Adsorbed)
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed a human clinical study that will be used to support expanding the indication for BioThrax(R) (Anthrax Vaccine Adsorbed) to...
Emergent BioSolutions Reports Financial Results for Third Quarter 2007
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the third quarter ended September 30, 2007. In addition, the company is raising its 2007 revenue guidance to now...
Emergent BioSolutions to Present at November Investor Conferences
Emergent BioSolutions Inc. (NYSE:EBS), announced today that company management will be presenting at two investor conferences during the month of...
Emergent BioSolutions to Release Third Quarter 2007 Financial Results on November 2, 2007; Management Will Conduct a Conference Call to Discuss Results as Well as Provide an Update on Business Developments
Emergent BioSolutions Inc. (NYSE:EBS), announced today that it will report financial results for the third quarter 2007 on Friday, November 2, 2007, before market...